ROYALTY PHARMA

Zenas BioPharma and Royalty Pharma announced a $300 million funding partnership to advance obexelimab development for IgG4-Related Disease and other autoimmune conditions.

Royalty Pharma acquired BeOne Medicines' royalty rights to IMDELLTRA (tarlatamab-dlle) for up to $950 million, with $885 million paid upfront and an option for additional $65 million within 12 months.

Revolution Medicines and Iambic Therapeutics announced a multi-year collaboration in July 2025 to develop novel drug candidates using AI-driven discovery platforms targeting RAS-addicted cancers.

Revolution Medicines partnered with Royalty Pharma on a $2 billion flexible funding agreement to support global development and commercialization of its RAS(ON) inhibitor portfolio for cancer treatment.

Royalty Pharma shareholders have overwhelmingly approved the acquisition of its external manager, with 99.9% voting in favor at the company's 2025 Annual General Meeting.

The FDA has approved Ferring Pharmaceuticals' new drug product manufacturing hub in Parsippany, NJ, for production of ADSTILADRIN, the first FDA-approved intravesical gene therapy for high-risk BCG-unresponsive bladder cancer.

Biogen has entered into a strategic funding agreement with Royalty Pharma, securing $250 million over six quarters to advance litifilimab, a promising lupus treatment, into Phase III development.

Syndax launched Revuforj (revumenib) for relapsed/refractory acute leukemia with KMT2A translocation, receiving NCCN guideline inclusion for AML and ALL.

• Vertex Pharmaceuticals reported its first commercial sale of Casgevy, a CRISPR gene therapy for sickle cell disease, generating $2 million in revenue from a patient infusion. • Intra-Cellular Therapies announced that Caplyta significantly reduced the risk of relapse in schizophrenia patients by 63% compared to placebo in a clinical trial. • Moderna's CEO is handing sales leadership to President Stephen Hoge following company reorganization and revised sales expectations for its RSV vaccine mResvia. • Syndax Pharmaceuticals sold royalty rights to Niktimvo, its chronic graft-versus-host disease drug, to Royalty Pharma for $350 million upfront to support its launch.

BRAIN Biotech AG заключила сделку по монетизации роялти на сумму до 128,88 млн евро с Royalty Pharma в отношении исследуемого фармацевтического соединения деукриктибант.